Download announcement as PDF
TRMED: Thor Medical's AlphaOne Facility to be Officially Opened by Norwegian Prime Minister Jonas Gahr Støre
2026-08-19 07:00:31
19.8.2026 07:00:10 CEST | Thor Medical ASA | Non-regulatory press releases
Thor Medical, a leading supplier of high-purity isotopes to the
radiopharmaceutical industry, today announced that its AlphaOne production
facility at Herøya Industrial Park will be officially opened by Norwegian Prime
Minister Jonas Gahr Støre on September 9, 2026.
AlphaOne is Thor Medical's first industrial-scale production facility for
high-purity alpha-emitting radioisotopes and the first facility of its kind in
the world. The facility is already in operation, producing isotopes for use in
next-generation targeted cancer therapies.
"We are pleased to welcome Prime Minister Jonas Gahr Støre to AlphaOne. The
facility represents an important step in building a reliable and scalable supply
of high-purity alpha emitters for the radiopharmaceutical industry, and we look
forward to marking this milestone together with our employees, partners and
guests," said Jasper Kurth, CEO of Thor Medical.
The opening ceremony is an invitation-only event. Members of the media wishing
to attend are asked to contact Mathias Nilsen Reierth at
mathias.reierth@thormedical.com for accreditation by September 7.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
www.thormedical.com - http://www.thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19028681/15379/Download%20announc
ement%20as%20PDF.pdf
no/ir-files/17848634/19028681/15379/Download%20announc\
ement%20as%20PDF.pdf\